Core Viewpoint - Viemed Healthcare (VMD) is identified as an attractive investment opportunity due to its strong growth, profitability, and technical strength, currently valued at $355 million [5]. Group 1: Company Overview - Viemed Healthcare is a home medical equipment supplier that provides post-acute respiratory care services through its subsidiaries Sleep Management L.L.C. and Home Sleep Delivered L.L.C. [1]. - The company has a market capitalization of $355 million and a trailing price-earnings ratio of 24.86x [6]. Group 2: Technical Performance - VMD has demonstrated strong technical momentum, trading at a new 2-year high of $9.96, with shares up more than 30% over the past 52 weeks [5][6]. - The stock has a Weighted Alpha of +57.28 and maintains a 100% "Buy" technical opinion from Barchart [6]. - VMD has made 12 new highs and is up 19.32% over the past month, with a Relative Strength Index (RSI) at 70.27 [6]. Group 3: Revenue Growth and Forecast - Revenue for Viemed is expected to grow by 16.71% this year and another 14.98% next year [6]. Group 4: Analyst and Investor Sentiment - Wall Street analysts have given VMD 1 "Strong Buy" and 1 "Hold" opinion, with a price target of $11 [7]. - Morningstar rates the stock as 15% undervalued, with a fair value of $10.92 [7]. - The stock has a short interest of 0.93% of the float, with 1.58 days to cover [7].

Core Viewpoint - Quipt Home Medical Corp. has successfully completed a transformative transaction, transitioning to a privately held entity through an arrangement agreement that involved the acquisition of all outstanding common shares for cash consideration of US$3.65 per share [1][2][3] Group 1: Transaction Details - The arrangement was executed under the Business Corporations Act (British Columbia) and involved 1567208 B.C. Ltd. as the purchaser, with funding from Kingswood Capital Management and Forager Capital Management [1][2] - Each outstanding option to acquire shares was deemed unconditionally vested and was surrendered for cash payment based on the difference between the consideration and the exercise price, with options being cancelled if the exercise price was equal to or greater than the consideration [3] - Restricted share units were also cancelled and exchanged for cash payment equal to the consideration [3] Group 2: Company Positioning and Future Outlook - The CEO expressed confidence that the transaction strategically positions the company for long-term success, emphasizing a commitment to clinical excellence and a patient-first approach [3] - Kingswood and Forager partners highlighted their intention to support the company and invest in its growth, aiming to build upon the existing momentum in home-based respiratory care [3] - Following the completion of the arrangement, Quipt's shares will be delisted from NASDAQ and the Toronto Stock Exchange, and the company plans to cease its public reporting obligations in Canada and the U.S. [4] Group 3: Company Overview - Quipt Home Medical Corp. specializes in in-home monitoring and disease management services, focusing on respiratory solutions and chronic disease management for patients in the U.S. healthcare market [7] - The company aims to expand its service offerings to include management of various chronic health conditions, enhancing its role in in-home patient care [7]

Core Viewpoint - Quipt Home Medical Corp. is set to be acquired by affiliates of Kingswood Capital Management and Forager Capital Management for US$3.65 per share, with the final court approval received for the arrangement, expected to close by March 16, 2026 [1]. Group 1: Acquisition Details - The Supreme Court of British Columbia issued a final order approving the acquisition plan under the Business Corporations Act [1]. - The cash consideration for the acquisition is US$3.65 per share [1]. - The completion of the arrangement is anticipated by March 16, 2026, assuming all conditions are met [1]. Group 2: Delisting and Reporting Status - Following the completion of the arrangement, the shares of Quipt Home Medical Corp. will be delisted from both the Toronto Stock Exchange and Nasdaq [2]. - The company will cease to be a reporting issuer in all jurisdictions where it currently reports under applicable securities laws [2]. Group 3: Company Overview - Quipt Home Medical Corp. specializes in in-home monitoring and disease management services, particularly focusing on respiratory care solutions for patients in the U.S. healthcare market [4]. - The company aims to expand its service offerings to manage various chronic diseases, including heart and pulmonary diseases, sleep disorders, and reduced mobility [4]. - The primary business objective is to provide a broader range of services for patients requiring in-home monitoring and chronic disease management [4].

March 4, 2026 Financial Supplement Fourth Quarter & Full Year 2025 This Financial Supplement contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indic ...

Core Viewpoint - Quipt Home Medical Corp. has received shareholder approval for a plan of arrangement involving the acquisition of all outstanding shares by affiliates of Kingswood Capital Management and Forager Capital Management for cash consideration of US$3.65 per share [1][2]. Group 1: Shareholder Meeting and Voting Results - The special meeting of shareholders was held on March 3, 2026, in Sarasota, Florida, where the Arrangement Resolution was approved [1]. - The Arrangement Resolution required at least 66⅔% of votes cast by shareholders, with 29,672,136 shares (approximately 66.93% of outstanding shares) represented at the meeting [2]. - The resolution was approved by 98.9% of the shares voted and 98.7% after excluding votes from interested parties as per MI 61-101 [2]. Group 2: Next Steps and Regulatory Approvals - The company is scheduled to seek a final order from the Supreme Court of British Columbia on March 5, 2026, to approve the arrangement [3]. - The completion of the arrangement is expected in the near term, pending satisfaction of all terms, conditions, and regulatory approvals [3]. Group 3: Company Overview - Quipt Home Medical Corp. provides in-home monitoring and disease management services, focusing on end-to-end respiratory solutions for patients in the U.S. healthcare market [5]. - The company aims to expand its offerings to manage various chronic diseases, enhancing shareholder value by providing a broader range of services [5]. - The organic growth strategy includes increasing annual revenue per patient by consolidating services and improving patient convenience [5].

Core Insights - AdaptHealth reported a challenging Q4 2025 with a net revenue of $846.3 million, down 1.2% year over year, attributed mainly to business dispositions in the Wellness at Home segment [5][6] - The company achieved full-year net revenue of $3.245 billion, slightly down 0.5% from the previous year, but with organic growth of 1.7% [6][7] - Management highlighted record patient census in multiple segments, indicating strong operational performance despite revenue declines [5][11] Financial Performance - Q4 net revenue breakdown: - Wellness at Home: $137.3 million, down 16.1% [2] - Diabetes Health: $158.5 million, down 7.4% [3] - Respiratory Health: $178.2 million, up 7.8% [4] - Sleep Health: $372.3 million, up 4.4% [4] - Adjusted EBITDA for 2025 was $616.7 million, with a margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million, with a margin of 19.3% [8] - Free cash flow for Q4 was $79.3 million, and for the full year, it was $219.4 million, exceeding guidance [9] Operational Developments - The company implemented a new operating model in 2025 to standardize workflows and improve service delivery, resulting in improved setup times for Sleep Health and Respiratory Health [11] - Technology pilots, including AI tools for order intake and patient scheduling, are expected to enhance operational efficiency in the future [12] - A new capitated contract went live in December 2025, covering about 50,000 members, with expectations to serve over 10 million patients nationwide [13] Guidance and Future Outlook - For 2026, AdaptHealth expects revenue growth of 6%-8% over 2025, with organic growth of 7.5%-9.5% [15] - Q1 2026 revenue growth is projected at 2%-3% year over year, with an Adjusted EBITDA margin of approximately 16% [16] - The company anticipates negative free cash flow in Q1 2026, with improvements expected as capitated revenue ramps up [16] Strategic Initiatives - AdaptHealth expanded its footprint with a Hawaii-based HME acquisition, marking its presence in the 48th state [17] - The company received a favorable outcome from CMS regarding competitive bidding, providing long-term stability for its core products [18] - A $14.5 million legal settlement related to a debt collection class action was finalized, with improvements in the company's control environment noted [19][20]

Core Viewpoint - Quipt Home Medical Corp. is moving forward with a plan of arrangement to be acquired by affiliates of Kingswood Capital Management and Forager Capital Management for cash consideration of US$3.65 per share, representing a 54% premium to its 30-day volume-weighted average price (VWAP) as of December 12, 2025 [1] Meeting Details - A special meeting for shareholders is scheduled for March 3, 2026, at 10:00 a.m. Eastern Standard Time, to vote on the Arrangement Resolution [1][3] - Only shareholders of record as of January 22, 2026, are entitled to vote at the meeting [3] Voting Requirements - The Arrangement Resolution requires approval from at least 66⅔% of the votes cast by shareholders present in person or by proxy, along with a simple majority excluding votes from interested parties as defined in Multilateral Instrument 61-101 [2] Shareholder Participation - Shareholders are encouraged to read the Circular and vote their shares before the proxy voting deadline of February 27, 2026, at 10:00 a.m. Eastern Standard Time [4] - Voting can be done in advance by proxy, regardless of attendance at the meeting [5] Board and Shareholder Support - The board of directors unanimously recommends that shareholders vote in favor of the Arrangement Resolution [7] - Directors and executive officers holding approximately 11.3% of shares have entered into Voting Support Agreements to vote in favor of the Arrangement [8] - Forager Fund, LP, holding approximately 9.5% of shares, has also agreed to vote in favor of the Arrangement [9] Legal Proceedings - The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the meeting to consider the Arrangement [10] Conditions for Implementation - The Arrangement is subject to obtaining final court approval, shareholder approval at the meeting, and satisfaction of other conditions outlined in the Arrangement Agreement dated December 14, 2025 [11] Company Overview - Quipt Home Medical provides in-home monitoring and disease management services, focusing on respiratory solutions and chronic disease management for patients in the U.S. healthcare market [13]

Viemed Healthcare FY Conference Summary Company Overview - **Company**: Viemed Healthcare (NasdaqCM: VMD) - **Industry**: Home medical provider specializing in respiratory therapy - **Unique Selling Proposition**: Focus on complex respiratory services for patients with severe conditions like COPD and neuromuscular diseases, providing care in the home to reduce hospital costs and improve quality of life [3][4] Core Business Segments - **Complex Respiratory Services**: 50% of revenue, targeting patients with severe respiratory issues [4] - **Sleep Apnea Services**: 20% of revenue, offering remote CPAP therapy and support [4] - **Oxygen Therapy**: 10% of revenue, catering to early-stage COPD patients [4] - **Staffing Division**: Developed post-COVID to address clinical labor shortages [5] - **Behavioral Health Component**: Supports respiratory therapy [5] Strategic Developments - **Growth and Diversification**: Transitioned from a 90% ventilator company to a diversified model with significant growth in sleep and other services [9][10] - **M&A Activity**: Completed three acquisitions to enhance service offerings and fill coverage gaps [9][10] - **National Coverage Determination (NCD)**: Achieved a competitive edge by working with CMS to establish new rules for home patient management [8] Financial Performance - **Revenue Growth**: Achieved a 27% compound annual growth rate (CAGR) driven by organic growth and expansion into underserved markets [17] - **Recurring Revenue**: Approximately 70% of revenue comes from recurring rental income, with 30% from transactional sales [20] - **Adjusted EBITDA Margin**: Currently around 22%, expected to remain stable despite diversification [26] Sales and Marketing Strategy - **High-Touch Sales Model**: Differentiates from competitors by integrating sales staff into hospital systems and providing continuous support [11][12] - **Sales Training**: Focus on training clinicians to become effective sales representatives, which is considered a key competitive advantage [15][16] Risk Management - **Payer Mix Strategy**: Maintains a diverse payer mix to mitigate risks associated with reliance on Medicare and other payers [22][23] - **Operational Leverage**: Implementing AI and technology solutions to enhance efficiency in billing and operations [24] Future Outlook - **Growth Opportunities**: Focus on expanding complex respiratory sales and maternal health services as key growth drivers for 2026 and beyond [36][37] - **Competitive Bidding Program**: Recent news indicates that Viemed's products will not be included in competitive bidding, reducing potential distractions for growth [38] Key Takeaways - Viemed Healthcare is positioned as a leader in home respiratory therapy with a strong focus on patient care and operational efficiency - The company has successfully diversified its offerings while maintaining strong financial performance and a positive growth trajectory - Future growth will be driven by strategic sales initiatives and expansion into new service areas, particularly maternal health

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of Quipt Home Medical Corp. to affiliates of Kingswood Capital Management, LP, where shareholders are expected to receive $3.65 per share in cash, raising questions about the fairness of the deal [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Transaction Details - The proposed transaction involves Quipt Home Medical Corp. selling to Kingswood Capital Management, with shareholders set to receive $3.65 per share [1]. - The investigation aims to determine if the deal is fair for shareholders [1].

Core Viewpoint - Quipt Home Medical Corp. reported strong financial results for Q4 and fiscal year 2025, highlighting organic growth and operational resilience despite industry challenges [5][6]. Financial Highlights - Q4 2025 revenue was $68.3 million, an 11% increase from $61.3 million in Q4 2024, with a sequential organic growth of 5% from Q3 2025 [6]. - Recurring revenue constituted 80% of total revenue in Q4 2025, driven by the resupply platform [6]. - Adjusted EBITDA for Q4 2025 was $14.9 million (21.8% of revenues), up from $13.4 million (21.9% of revenues) in Q4 2024, marking an 11% increase [6]. - Fiscal year 2025 revenue was $245.4 million, slightly down from $245.9 million in fiscal year 2024 [6]. - Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% of revenue), compared to $57.7 million (23.5% of revenue) in fiscal year 2024, representing a 3% decrease [6]. - Net loss for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to a loss of ($2.9) million, or ($0.07) per diluted share in Q4 2024 [6]. - Net loss for fiscal year 2025 was ($10.7) million, or ($0.24) per diluted share, compared to ($6.8) million, or ($0.16) per diluted share in fiscal year 2024 [6]. - Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, up from $35.4 million for the year ended September 30, 2024 [6]. - The company had $12.9 million in cash on hand as of September 30, 2025, compared to $11.3 million as of June 30, 2025 [6]. - The Net Debt to Adjusted EBITDA Leverage Ratio was 1.8x, indicating a conservative balance sheet [6][14]. Operational Highlights - The customer base increased by 10% year over year, serving 346,000 unique patients in fiscal year 2025 compared to 314,000 in fiscal year 2024 [6]. - Unique set-ups/deliveries rose to 917,000 in fiscal year 2025, a 7% increase from 854,000 in fiscal year 2024 [6]. - Respiratory resupply set-ups/deliveries increased by 1% to 486,000 in fiscal year 2025 from 480,000 in fiscal year 2024, attributed to technology and centralized intake processes [6].